GSK Brings Cervarix To India At Higher Price Than Merck's Gardasil; Will Gynecologists and Pediatricians Help GSK Grab Market Share?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Overcoming a drawn-out registration and approval process, GlaxoSmithKline has finally launched its much awaited vaccine Cerverix in India. Cerverix is used for the prevention of pre-malignant cervical lesions and cervical cancer related to human pappilomavirus (HPV) types 16 and 18
You may also be interested in...
GSK Eases Cervarix Out Of India, Eyes On Trajectory Of Synflorix
GSK discontinues Cervarix in India as part of portfolio rationalization efforts against the backdrop of the arrival of Serum’s 'affordable' quadrivalent HPV vaccine. The heat is also believed to be on the UK drugmaker’s pneumococcal vaccine Synflorix in the country.
India’s Supreme Court To Govt: Respond To Charges Of Safety Breech In Gardasil, Cervarix
In the latest of a series of court interventions, the Supreme Court has asked the regulatory agency to come clear on approvals for Gardasil and Cervarix.
International Vaccine Institute Forms Partnerships To Expedite Addition Of HPV Vaccine To Asia Pacific Immunization Programs
SEOUL - The International Vaccine Institute held a symposium June 1-2 in Seoul to forge public-private partnerships to encourage governments to include the human papillomavirus to their immunization programs in Asia-Pacific and the Middle East